Cresco Labs Balance Sheet Health
Financial Health criteria checks 3/6
Cresco Labs has a total shareholder equity of $365.4M and total debt of $424.9M, which brings its debt-to-equity ratio to 116.3%. Its total assets and total liabilities are $1.4B and $1.0B respectively. Cresco Labs's EBIT is $117.3M making its interest coverage ratio 2.1. It has cash and short-term investments of $153.3M.
Key information
116.3%
Debt to equity ratio
US$424.86m
Debt
| Interest coverage ratio | 2.1x |
| Cash | US$153.30m |
| Equity | US$365.37m |
| Total liabilities | US$1.02b |
| Total assets | US$1.38b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CRLB.F's short term assets ($311.9M) exceed its short term liabilities ($158.6M).
Long Term Liabilities: CRLB.F's short term assets ($311.9M) do not cover its long term liabilities ($859.0M).
Debt to Equity History and Analysis
Debt Level: CRLB.F's net debt to equity ratio (74.3%) is considered high.
Reducing Debt: CRLB.F's debt to equity ratio has increased from 0% to 116.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CRLB.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CRLB.F is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.1% per year.